Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

NCT06961357 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Interleukin-2
DRUG: TIL Product

Sponsor

H. Lee Moffitt Cancer Center and Research Institute